Hydromorphone

Generic Name
Hydromorphone
Brand Names
Dilaudid, Exalgo, Hydromorph Contin, Hydromorphone Hp Forte
Drug Type
Small Molecule
Chemical Formula
C17H19NO3
CAS Number
466-99-9
Unique Ingredient Identifier
Q812464R06
Background

Hydromorphone is a pure opioid, a semi-synthetic hydrogenated ketone derivative of morphine that has been available clinically since 1920. Structurally, hydromorphone derived from morphine in the modification of the hydroxyl group in the carbon 6 to a carbonyl and the absence of a double bond between the carbon 7 and 8. Due to these modifications, it present...

Indication

Hydromorphone is indicated for the management of moderate to severe acute pain and severe chronic pain. Due to its addictive potential and overdose risk, hydromorphone is only prescribed when other first-line treatments have failed.
...

Associated Conditions
Neuropathic Pain, Refractory Chronic Cough, Moderate to severe pain
Associated Therapies
-
Clinical Trials
Related News

Protocolized vs Nonprotocolized Treatment of Adult ED Patients With Acute Severe Pain

Phase 3
Completed
Conditions
Acute Pain
Interventions
Drug: Nonprotocolized
Drug: Hydromorphone
First Posted Date
2008-03-03
Last Posted Date
2018-04-05
Lead Sponsor
Montefiore Medical Center
Target Recruit Count
224
Registration Number
NCT00627367
Locations
🇺🇸

Montefiore Medical Center, Bronx, New York, United States

The Discriminative Effects of Tramadol in Humans

First Posted Date
2007-07-11
Last Posted Date
2017-10-17
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Target Recruit Count
20
Registration Number
NCT00499746
Locations
🇺🇸

Behavioral Pharmacology Research Unit, Baltimore, Maryland, United States

An Open-label Study of Hydromorphone Oral Solution in Subjects Aged 28 Days to 16 Years for Postoperative Pain

Phase 4
Completed
Conditions
Postoperative Pain
Interventions
Drug: Hydromorphone
First Posted Date
2007-04-25
Last Posted Date
2015-11-18
Lead Sponsor
Purdue Pharma LP
Target Recruit Count
116
Registration Number
NCT00465647
Locations
🇺🇸

Children's Hospital Medical Center of Akron, Akron, Ohio, United States

🇺🇸

Children's Hospital of Orange County - Pediatric Subspecialty, Orange, California, United States

🇺🇸

Stanford University Medical Center, Stanford, California, United States

and more 11 locations

Trial Comparing Morphine to Hydromorphone in Elderly Patients With Severe Pain

Phase 2
Completed
Conditions
Acute Pain
Interventions
Drug: Morphine
Drug: Hydromorphone
First Posted Date
2006-03-21
Last Posted Date
2018-08-20
Lead Sponsor
Montefiore Medical Center
Target Recruit Count
194
Registration Number
NCT00305058
Locations
🇺🇸

Montefiore Medical Center, Bronx, New York, United States

Effects of Post-Session Supplemental Hydromorphone on Drug Seeking Behavior in Opioid Dependent Individuals

First Posted Date
2005-09-22
Last Posted Date
2012-06-05
Lead Sponsor
Wayne State University
Target Recruit Count
16
Registration Number
NCT00218361
Locations
🇺🇸

Wayne State University, Detroit, Michigan, United States

Effects of Pre-Session Supplemental Hydromorphone on Drug Seeking Behavior in Opioid Dependent Individuals

First Posted Date
2005-09-22
Last Posted Date
2017-01-12
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Target Recruit Count
16
Registration Number
NCT00218309
Locations
🇺🇸

Wayne State University, Detroit, Michigan, United States

Safety and Efficacy Study of Hydromorphone and Morphine

Phase 2
Completed
Conditions
Pain
Interventions
Drug: Morphine
Drug: Hydromorphone
First Posted Date
2005-09-20
Last Posted Date
2018-08-15
Lead Sponsor
Montefiore Medical Center
Target Recruit Count
198
Registration Number
NCT00195910
Locations
🇺🇸

Montefiore Medical Center, Bronx, New York, United States

Topical Hydromorphone for Wound Healing

Phase 1
Terminated
Conditions
Wound Healing
First Posted Date
2005-09-15
Last Posted Date
2010-03-01
Lead Sponsor
Hordinsky, Maria K., MD
Target Recruit Count
50
Registration Number
NCT00177060
Locations
🇺🇸

University of Minnesota, Minneapolis, Minnesota, United States

Abuse Potential of Buprenorphine and Naloxone in Non-Dependent Opioid Users

Not Applicable
Completed
Conditions
Opioid-Related Disorders
First Posted Date
2005-09-12
Last Posted Date
2017-01-12
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Target Recruit Count
7
Registration Number
NCT00158236
Locations
🇺🇸

Johns Hopkins University (BPRU) Bayview Campus, Baltimore, Maryland, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy